Pazopanib

Catalog No.S3012 Synonyms: GW786034

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 27 Publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell NUjEXHhRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGfDTXRKdmirYnn0bY9vKG:oIHj1cYFvKEWxTD2xMYNmdGxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygbYM2OD1{Lki5[U0xPSEQvF2= NVftRlB{W0GQR1XS
human AN3-CA cell M1KzZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mkf3TY5pcWKrdHnvckBw\iCqdX3hckBCVjNvQ1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE4xPSCwTR?= M2XiWXNCVkeHUh?=
human CGTH-W-1 cell MkToS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmmzTY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQxNjBzIH7N NVPrTGtWW0GQR1XS
human GDM-1 cell M{LGZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYnnZ4lwUW6qaXLpeIlwdiCxZjDoeY1idiCJRF2tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExOy57OTDuUS=> NUTQeoE4W0GQR1XS
human A204 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVLNTGo5UW6qaXLpeIlwdiCxZjDoeY1idiCDMkC0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVA6NjB4IH7N MWPTRW5ITVJ?
human G-402 cell M4nTbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M17pW2lvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21N|EvQDRibl2= M1;EVnNCVkeHUh?=
human MFE-296 cell NF36O4JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWPJcohq[mm2aX;uJI9nKGi3bXHuJG1HTS1{OU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6ODJ{IN88US=> MkfPV2FPT0WU
human NOS-1 cell Mn;FS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFrLN3ZKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKGmlNUC9NE43PTl6NzFOwG0> M3XLXXNCVkeHUh?=
human KG-1 cell Ml;5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M13sOmlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|E4PTVizszN M{XBWnNCVkeHUh?=
human HT55 cell M1[3Rmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGPKNXZKdmirYnn0bY9vKG:oIHj1cYFvKEiWNUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5PzhzIN88US=> NWPmTlkzW0GQR1XS
human MG-63 cell NX3WXYd6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYHJcohq[mm2aX;uJI9nKGi3bXHuJG1INTZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6wNFE1PiEQvF2= MVTTRW5ITVJ?
human CCF-STTG1 cell M13uSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mlu1TY5pcWKrdHnvckBw\iCqdX3hckBES0ZvU2TUS|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5Nige,:jDDJR|UxRTFwMES5PFEh|ryP NUTUVlhvW0GQR1XS
human RT-112 cell MnTUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkfJTY5pcWKrdHnvckBw\iCqdX3hckBTXC1zMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlExOzd4IN88US=> MY\TRW5ITVJ?
human MC-IXC cell M2fHfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlrZTY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlEyPTF{IN88US=> MU\TRW5ITVJ?
human HUTU-80 cell MofNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFrybHRKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ6MUCzJO69VQ>? NGr5Wm1USU6JRWK=
human MV-4-11 cell NX;PS2kzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mln5TY5pcWKrdHnvckBw\iCqdX3hckBOXi12LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{PDVyMTFOwG0> M1rtXnNCVkeHUh?=
human LCLC-103H cell Ml7JS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXTJcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvMUCzTEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 MlfuV2FPT0WU
human G-401 cell M4H2Zmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1TOdGlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ3PDJzIN88US=> MXTTRW5ITVJ?
human A704 cell MkPSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnPFTY5pcWKrdHnvckBw\iCqdX3hckBCPzB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NFMzOyEQvF2= MnfnV2FPT0WU
human ESS-1 cell Mo\iS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NITWWYtKdmirYnn0bY9vKG:oIHj1cYFvKEWVUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43ODN7NjFOwG0> MUPTRW5ITVJ?
human HLE cell NIK2OI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGHnUFZKdmirYnn0bY9vKG:oIHj1cYFvKEiORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlM5ODRizszN M4KxS3NCVkeHUh?=
human NY cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2XZTGlvcGmkaYTpc44hd2ZiaIXtZY4hVlliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLki0PFIyKM7:TR?= NWLPXmN2W0GQR1XS
human A427 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXzJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkm4NFc2KM7:TR?= M{HMcnNCVkeHUh?=
human SK-N-DZ cell NIizNG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFixVVlKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB{M{ixJO69VQ>? MonoV2FPT0WU
human J82 cell NHrhW4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2fzcmlvcGmkaYTpc44hd2ZiaIXtZY4hUjh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6wOlA5QCEQvF2= MkC0V2FPT0WU
human GI-1 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmrITY5pcWKrdHnvckBw\iCqdX3hckBIUS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yNlk2OSEQvF2= M{PhUXNCVkeHUh?=
human NCI-H716 cell NIXObpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{G2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{OTZ|MzFOwG0> NEfIVWFUSU6JRWK=
human SF126 cell Ml[zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnwZ4tKdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41PzR3OTFOwG0> Mn\VV2FPT0WU
human H4 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MojETY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUGyOlIh|ryP MnzjV2FPT0WU
human LB831-BLC cell MnLXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV35WXYzUW6qaXLpeIlwdiCxZjDoeY1idiCOQkizNU1DVENiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkW0OVY3KM7:TR?= NX3uVZRkW0GQR1XS
human HCC1395 cell NXziWnpFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUGwUZRsUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxN|k2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53OEG1OkDPxE1? M1;3bXNCVkeHUh?=
human LK-2 cell M3fpNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NInHRXJKdmirYnn0bY9vKG:oIHj1cYFvKEyNLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlY1PTZ7IN88US=> NV;SXJNKW0GQR1XS
human G-361 cell M2HhbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVzydZFXUW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODRyOEKg{txO NXz3Z|FYW0GQR1XS
human NCI-H2342 cell MoD4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkO0NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NiCLQ{WwQVMvOTN|MU[g{txO MYLTRW5ITVJ?
human SK-LU-1 cell  MkfNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn7wTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OVT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yQDd4NzFOwG0> MoS3V2FPT0WU
human IGROV-1 cell  NVjJZVFwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MULJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI1PzF|IN88US=> M1PZ[nNCVkeHUh?=
human EB2 cell NFO5eVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYnWb3VQUW6qaXLpeIlwdiCxZjDoeY1idiCHQkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI5OTZ6IN88US=> MUXTRW5ITVJ?
human CAL-54 cell M3XDXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVTJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlg{PjdizszN MVrTRW5ITVJ?
human LB1047-RCC cell NEPXZo9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mmf3TY5pcWKrdHnvckBw\iCqdX3hckBQS1WELV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlM{OTN4ODFOwG0> M1W2fXNCVkeHUh?=
Daudi cell M2\OO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF3xXXRKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkWzNVY1KM7:TR?= Mn;XV2FPT0WU
human Daudi cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MULJcohq[mm2aX;uJI9nKGi3bXHuJGRifWSrIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62OlIyQSEQvF2= MVLTRW5ITVJ?
human A172 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWHJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkezO|kh|ryP NYHtO5JVW0GQR1XS
human KGN cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmDzTY5pcWKrdHnvckBw\iCqdX3hckBMT05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkC2O|A6KM7:TR?= MX3TRW5ITVJ?
human SNG-M cell NIfVNmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1r2PWlvcGmkaYTpc44hd2ZiaIXtZY4hW06JLV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlA5PjZ7IN88US=> NUPpXIJuW0GQR1XS
human SW1710 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{faeWlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PzNzODFOwG0> NXrtXJFiW0GQR1XS
human HT29 cells NVTMdXFtWHKxbHnm[ZJifGmxbjDhd5NigQ>? MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWMkmgZ4VtdHNiaX6gd4VzfW1iY3;ueIFqdmmwZzDt[YRqfW1? NYDBSnA{OTh4MkCzPFI>
human A375P cells MYjQdo9tcW[ncnH0bY9vKGG|c3H5 NGi3b2VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|VRKGOnbHzzJIlvKHOncoXtJINwdnSjaX7pcochdWWmaYXt NXzRfJJTOTh4MkCzPFI>
human HN5 cells NYSwWXlQWHKxbHnm[ZJifGmxbjDhd5NigQ>? NUfzSmdiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUlUh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= MnGxNVg3OjB|OEK=
HUVEC NF\Fc45HfW6ldHnvckBie3OjeR?= MYixJO69VQ>? NUH2WG5XPiCq MV\BcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3YnWg[o9zdWG2aX;uJIF1KDBwMTD1UUBi\nSncjC2JIhzeyCkeTDNZZRzcWenbDDhd5NigQ>? NXHXUnJzOjRyM{[wOFI>
human Daoy cell MkDuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2PzSWlvcGmkaYTpc44hd2ZiaIXtZY4hTGGxeTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuO|c6PDlizszN MVPTRW5ITVJ?
human DMS-273 cell Mmj0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWe1d3lnUW6qaXLpeIlwdiCxZjDoeY1idiCGTWOtNlc{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57NkKwNkDPxE1? MX3TRW5ITVJ?
human KU812 cell NF7TXXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVPZb5Y2UW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzd6MUKg{txO MlTLV2FPT0WU
human NCI-H727 cell NVTC[|huT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1u5emlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3Nlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjRyOUCxJO69VQ>? NVj1foJOW0GQR1XS
human P30-OHK cell NWW4OlZ7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWjJcohq[mm2aX;uJI9nKGi3bXHuJHA{OC2RSFugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ3QTRizszN M1fJdnNCVkeHUh?=
human MIA-PaCa-2 cell NGDCXWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUP2c2xuUW6qaXLpeIlwdiCxZjDoeY1idiCPSVGtVIFE[S1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT62NFQ3PiEQvF2= NVv0RlVEW0GQR1XS
human TT cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHvU[2FKdmirYnn0bY9vKG:oIHj1cYFvKFSWIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT62OlI1KM7:TR?= MXPTRW5ITVJ?
human DK-MG cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MljtTY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|IxOjhizqzt MWXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / PUMA ; 

PubMed: 27924057     


The expression of p53 or PUMA by western blotting analysis in HCT-116 cells treated with (left) 20 μM pazopanib for indicated hours or (right) with 1-20 μM pazopanib for 24 hours.

p-Akt / Akt ; 

PubMed: 27924057     


Akt is inhibited after pazopanib treatment in colon cells. The expression of P-Akt (S473) was detected by western blotting in (A) RKO or HT-29 cells after 20 μM pazopanib treatment for indicated times.

27924057
Growth inhibition assay
Cell viability; 

PubMed: 27924057     


Cell viability was analyzed using Cell Counting Kit-8 at 0, 3, 6, 12 and 24 hours after 1, 5, 10, or 20 μM pazopanib treatment in HCT-116 cells. Data represent the mean ± SEM of four independent experiments.

27924057
In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

- Collapse
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
Synonyms GW786034

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03735758 Recruiting Drug: pazopanib or guideline conform chemotherapy Soft Tissue Sarcoma Adult GWT-TUD GmbH November 2 2018 Phase 4
NCT03334409 Recruiting Drug: Ascorbic Acid|Drug: Pazopanib Hydrochloride Clear Cell Renal Cell Carcinoma|Metastatic Clear Cell Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v7|Unresectable Renal Cell Carcinoma Academic and Community Cancer Research United|National Cancer Institute (NCI) February 16 2018 Phase 2
NCT03149120 Withdrawn Biological: Nivolumab|Drug: Pazopanib Soft Tissue Sarcomas NYU Langone Health|Bristol-Myers Squibb August 2017 Phase 2
NCT02979899 Completed Biological: TRC105|Drug: Votrient Advanced Angiosarcoma Tracon Pharmaceuticals Inc. February 13 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID